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Abstract
Background: Dystonias (Dys) represent the third most common movement disorder after essential tremor (ET) and Parkinson’s disease (PD). While some pathogenetic
mechanisms and genetic causes of Dys have been identified, little is known about their neuropathologic features. Previous neuropathologic studies have reported generically
defined neuronal loss in various cerebral regions of Dys brains, mostly in the basal ganglia (BG), and specifically in the substantia nigra (SN). Enlarged pigmented neurons in
the SN of Dys patients with and without specific genetic mutations (e.g., GAG deletions in DYT1 dystonia) have also been described. Whether or not Dys brains are
associated with decreased numbers or other morphometric changes of specific neuronal types is unknown and has never been addressed with quantitative methodologies.
Methods: Quantitative immunohistochemistry protocols were used to estimate neuronal counts and volumes of nigral pigmented neurons in 13 SN of Dys patients and 13
SN of age-matched control subjects (C).
Results: We observed a significant reduction (,20%) of pigmented neurons in the SN of Dys compared to C (p,0.01). Neither significant volumetric changes nor evident
neurodegenerative signs were observed in the remaining pool of nigral pigmented neurons in Dys brains. These novel quantitative findings were confirmed after exclusion of
possible co-occurring SN pathologies including Lewy pathology, tau-neurofibrillary tangles, b-amyloid deposits, ubiquitin (ubiq), and phosphorylated-TAR DNA-binding
protein 43 (pTDP43)-positive inclusions.
Discussion: A reduced number of nigral pigmented neurons in the absence of evident neurodegenerative signs in Dys brains could indicate previously unconsidered
pathogenetic mechanisms of Dys such as neurodevelopmental defects in the SN.
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Introduction
Dystonias (Dys), which manifest either as an isolated abnormal
motor phenomenon or in combination with other motor and
nonmotor signs of more complex neuropsychiatric syndromes,
represent a relatively frequent movement disorder.1,2 Dys, in fact,
represent the third most frequent movement disorder after essential
tremor (ET) and Parkinson’s disease (PD).3
A number of efforts have led to various classification systems of Dys,4–8
attempts to characterize their biological bases,9–13 and multiple pro-
posals of clinical guidelines for their treatment.14–16 However, although
important progress has been achieved in understanding some of the
neurological bases of Dys, especially in terms of molecular mechanisms17
and genetic causes,18 the distinct characteristic neuropathologic features
of Dys remain poorly defined19 with some very rare exceptions.20,21
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There have been few clinicopathologic correlation studies of
postmortem brain tissues from Dys patients, with most analyses
described in sporadic case-reports.22–27 These neuropathologic studies
have proven to be mostly inconclusive due to the clinical heterogeneity
of Dys cases examined, the different classification systems used, and
more importantly, difficulty in obtaining brains from clinically well-
characterized Dys patients.28 However, a few neuropathologic studies
have begun to shed light on possible neuropathologic and morpho-
metric aspects of specific types of Dys, such as DYT1-dystonia
(DYT1),29 cervical dystonia (CD)30, and dopa-responsive dystonia
(DRD).31 Rostasy and colleagues assessed brains from five patients
with DYT1 (GAG-deletions) and three Dys patients without GAG-
deletions and reported larger and more compacted pigmented neurons
in the substantia nigra (SN) of both types of Dys compared to control
subjects (C).29 In contrast, Go¨ttle et al. described smaller SN neurons
in Lesch-Nyhan disease.32 In general, these lines of evidence support
the hypothesis that the SN is indeed involved in Dys pathogenesis.33–35
The primary aim of this study was to investigate morphometric
aspects of neuromelanin-containing (pigmented) neurons in the SN of
Dys patients by performing rigorous neuropathologic quantitative
analyses. We aimed to estimate nigral pigmented neuronal counts and
cell body, nuclear, and nucleolar volumes using established quantifica-
tion methods and the largest number of publicly available Dys autopsy
brains to date.
We observed a significant decrease in the number of pigmented
neurons in the SN of Dys brains versus C. This reduction was present
in the SN of patients with both adulthood- and childhood-onset Dys.
Interestingly, fewer pigmented neurons in the SN were not associated
with significant changes in cellular, nuclear, or nucleolar volumes of
the remaining pool of nigral pigmented neurons, or with other major
neuropathologic and neurodegenerative signs. These findings might
indicate that a reduction in SN pigmented neurons in Dys patients
could be due to a neurodevelopmental defect rather than a
neurodegenerative process.
A nigral pigmented neuronal reduction in the absence of cellular
(cell body) and subcellular (nuclear/nucleolar) volumetric changes in
the SN of Dys brains was confirmed by excluding other possible
confounding or co-occurring nigral pathologies with immunohisto-
chemistry protocols. In this study, the Dys and C groups did not differ
in terms of mean age at death, further minimizing the influence of the
important confounding factor of age.36
Methods
A total of 13 SN from patients (9 females and 4 males) with various
Dys subtypes were available for this study. The mean age at death was
68.8¡15.5 years (range: 44–95). These individuals had a history of
childhood- or adulthood-onset Dys with focal, segmental, or general-
ized distribution. Dys cases did not show signs of any other major
neurological, psychiatric, or medical disorders except for one patient
with diagnosis of possible dementia with Lewy bodies (possDLB), and
another with cardiovascular disease. Cases of DYT1, the most frequent
genetic form of Dys, were excluded from this investigation to avoid
performing measurements on neurons from the brains of patients with
Dys attributable to specific genetic causes. With this exclusion, we
aimed to obtain general but specific quantitative findings on non-
DYT1 or idiopathic Dys only.
The 13 SN from Dys patients were compared to 13 SN from age-
matched control subjects (C, 9 females and 4 males). The mean age at
death was 64.3¡13.8 years (range: 44–88 years). C did not show
clinical or pathologic evidence of any major neurological, psychiatric,
or medical disorders except for heart disease in some cases.
In addition to the standard microscopic neuropathological assess-
ments, all SNs were immunohistochemically assessed for the presence
of: a-synuclein-positive Lewy bodies (LB) and Lewy neurites (LN),
hyperphosphorylated-tau neurofibrillary tangles (tau-NFT), hyperpho-
sphorylated-tau threads (tau-th), ubiquitin (ubiq), intraneuronal
cytoplasmic inclusions of phosphorylated-TAR-DNA binding pro-
tein-43 (pTDP-43), and extracellular deposits of insoluble 1–42
b-amyloid (diffuse-Ab and Ab-neuritic plaques). Subjects with neuro-
pathologic findings indicative of any other neurodegenerative disorder
or severe cerebrovascular disease were excluded from the study.
All Dys and C brains were collected after obtaining written consent
from the next-of-kin or legal representative and after approval from
each institution where the case was examined. Tissues were obtained
from the University of Maryland Brain and Tissue Bank (UMBTB).
The use of these tissues was approved by UMBTB and the local
Institutional Research Board. Each hemibrain was fixed in 10%
buffered formalin for at least 2 weeks and then grossly and
microscopically examined in coronal sections for a general neuro-
pathologic assessment at UMBTB.
Neuropathology and quantitative methods
Each hemi-SN block was randomly cut at different anatomical levels
along the rostro-caudal anatomical axis of the structure. This
anatomically random cutting minimized possible anatomical selection
biases. We were unable to obtain the entire SN for each subject, but
we were confident that at least three quarters of the entire structure
was actually sampled for each case. This conclusion was based on our
samples measurements (see below) in comparison to previous
anatomical studies that assessed the entire length of SN.37,38
Tissue cutting and procedures for morphometric-quantitative
analyses
The total length of each block of formalin-fixed SN received ranged from
8–10 mm. Tissues were processed at the Neuropathology Research labs at
the Biomedical Research Institute of New Jersey (BRInj). Tissue blocks were
processed with an automated tissue-processor (Tissue-Tek V.I.P. 1000
Vacuum Infiltration Processor, Ames Division, Miles Laboratories, Inc.,
Elkhart, IN, USA) using standard protocols. Tissue blocks were then
embedded in paraffin, oriented with the rostral area facing the bottom of the
paraffin mold, and serially cut along the rostro-caudal direction using a
semi-automatic microtome (Leica RM2255, Leica Biosystems, Nussloch,
Germany). Each block was cut for its entire length in series of 40 mm-thick
consecutive sections, alternating to a series of 16 consecutive 10 mm-thick
Iacono D, Geraci-Erck M, Peng H, et al. Fewer Nigral Pigmented Neurons in Dystonia
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services2
sections. These serial, consecutive, and alternating sectioning procedures
guaranteed the constancy of the established sampling rate for this
investigation (one every five 40 mm-thick sections) and simultaneously
allowed the use of 10 mm-thick consecutive sections anatomically adjacent
to the 40 mm-thick sections for further immunohistochemistry assessments
and volumetric measurements.39
The mean length of the sampled SN did not differ between Dys and
C brains (mean lengths of 9,392.31¡1,518.99 mm and
10,015.38¡1,573.2 mm, respectively). The total number of consecu-
tive sections (including 40 mm- and 10 mm-thick sections) obtained for
Dys and C were 792.9¡129.3 and 845.4¡132.3, respectively. No
statistical differences in terms of total length of sampled tissue and
number of sections obtained were present between the Dys and C
groups. Means of 48.6¡7.5 and 51.6¡7.5 40 mm-thick consecutive
sections were respectively obtained for Dys and C.
Each set of 40 mm-thick sections was stained with a 1.0% cresyl
violet (CV) solution for neuronal counting.40 Each set of 40 mm-thick
sections was separately and randomly recoded by an investigator
blinded to the clinical and pathologic diagnoses (M.G.E.). Quantitative
measurements using well-established stereological probes (the Optical
Fractionator and Nucleator, see below) were performed by a second
investigator (D.I.). Slides codes were opened, and statistical analyses
were performed only after all measurements were completed.
A single 10 mm-thick tissue section was randomly chosen, stained with
hematoxylin and eosin (H&E), and microscopically inspected at low
(2.56) and high (206) magnifications to assess for possible micro-
ischemic vascular pathologies, microhemorrhages, tissue rarefaction, and
other possible histologic abnormalities not visible on gross examination.
Procedures for SN neuropathologic quantitative measurements
Each section was stereoscopically inspected (26) across the entire
sectional area to localize SN anatomical borders. The pars compacta
and pars reticulata were identified and marked as based on previous
detailed anatomical descriptions.41
For neuronal counting, the following histologic criteria were
applied:
1) Use of 40 mm-thick sections;
2) Inclusion of any neuron, of any size, containing neuromelanin
pigment;
3) Exclusion of nonneuronal cells containing neuromelanin pigment,
such as macrophages.
For neuronal volumetric measurements, the following histologic
criteria were applied:
1) Use of 10 mm-thick sections;
2) Individuation of a well-defined nonneuromelanin-covered nucleo-
lus for each randomly sampled pigmented neuron;
3) Establishing the nucleolus as the only point of reference for all
volumetric measurements in each randomly sampled pigmented
neuron.
Measurements were performed using the Stereo-Investigator system,
Version 10.0 (MBF Bioscience, Williston, VT, USA), equipped with a
digital camera (AxioCam MRm, and MRc, Zeiss, Oberkochen,
Germany) and multiple objective head (2.5–1006 oil-immersion). The
sampling grid area was 5006500 mm, the counting frame was
40640 mm, and the disector height was 25 mm with guard zones of
¡2 mm. The total number of SN pigmented neurons was estimated
using the Optical Fractionator probe.42,43
Series of 10 mm-thick consecutive sections adjacent to each
previously analyzed 40 mm-thick section were stained with CV to
measure the cellular, nuclear, and nucleolar volumes of pigmented
neurons. Volumetric measurements were performed using the
Nucleator probe.38 Pigmented neuron volumes were measured by
placing six rays that automatically centered on the nucleolus and
randomly intersecting the cell membrane (Figure 1A). Pigmented
neurons were measured if their nucleolus was inside the counting
frame intersecting or touching the green inclusion line; they were
excluded if their nucleolus intersected or touched the red exclusion line
(Figure 1A, upper right quadrant). This second-run of volumetric
measurements on separate sets of 10 mm-thick consecutive sections was
chosen to increase the number of available pigmented neurons
showing a well-defined nucleolus, that is, the established point of
spatial reference for volumetric measurements in this study. In fact, a
consistent number of pigmented neurons that could be clearly counted
on 40 mm-thick sections could not be volumetrically measured due to
the presence of neuromelanin covering, partially or totally, the
nucleolus (Figure 1B).
Immunohistochemistry
Each Dys and C case underwent an extensive immunohistochemical
assessment. For each case, we examined 16 10-mm thick sections
adjacent to the median 40 mm-thick set of sections. The 10 mm-thick
tissue sections were deparaffinized, hydrated, and treated to block
endogenous peroxidase activity (3% hydrogen peroxide in water).
They were then rinsed in buffer (Tris with 0.05% Triton-X),
microwaved with antigen retrieval solution (sodium citrate, pH 6.0)
for 10 minutes, and cooled. Protein block (1.5% horse serum) was
applied for 30 minutes. The following antibodies were used: mouse
anti-b-amyloid, 17–24 (dilution 1:500, 4G8; SIG-39220, Covance,
Princeton, NJ, USA) with overnight incubation at 4 C˚ (sections were
pre-treated with 90% formic acid, 5 minutes); mouse anti-PHF-tau
(dilution 1:500, MN1020; Thermo Fisher Scientific, Waltham, MA,
USA); mouse anti-a-synuclein (dilution 1:500, Ab27766; Abcam,
Cambridge, UK) rabbit anti-ubiq (dilution 1:250, ab7780, Abcam);
rabbit anti phospho-TDP-43 (dilution 1:2,000, TIP-PTD-P02; Cosmo
Bio Co. LTD, Carlsbad, CA, USA). With the exception of the anti-b-
amyloid antibody, sections were incubated overnight at 4 C˚, rinsed
with buffer, incubated with biotinylated horse anti-mouse or anti-
rabbit secondary antibodies (30 minutes), Vector Kit reagents (Vector
Labs, Inc., Burlingame, CA, USA), then with a 3, 3’-diaminobenzidine
substrate system (D3939; Sigma, St. Louis, MO, USA) for 5 minutes.
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Slides were counterstained with hematoxylin, dehydrated in xylene,
and coverslipped.
Statistical analyses
Statistical analyses for quantification and volumes were performed
to compare Dys and C, adulthood-onset Dys and C, childhood-onset
Dys and C, childhood-onset Dys and adulthood-onset Dys, and
generalized and segmental/focal Dys. All comparisons were computed
before and after excluding co-occurring pathology (LB, LN, tau-NFT,
tau-th, ubiq, and pTDP43 inclusions, b-amyloid deposits). The
childhood-onset Dys group included subjects with early adulthood-
onset diagnoses and the only subject with posttraumatic Dys (Dys#10,
onset at age 12).
Neuronal counting results revealed a Gaussian distribution, and a
t-test was initially performed to compare Dys and C and Dys and C
without copathologies. Furthermore, we performed analyses of
variance (ANOVAs) with Tukey’s posthoc tests across all comparisons.
The Tukey’s test compares every mean with every other mean and
takes into account multiple comparisons and adjusted p-values for each
comparison. Statistical significance was established at p,0.01 (adjusted
for all five types of comparisons).
The preliminary analyses for the obtained neuronal volumetric
measurements did not show a Gaussian curve, so nonparametric
Mann-Whitney tests were performed across all comparisons for those
measurements. Data refer to the values estimated for the bilateral SN.
All computations were performed using GraphPad Prism software,
version 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
The demographic, medical, and genetic data for both the Dys and C
groups are summarized in Table 1. Table 1 shows diagnoses of Dys as
received from UMBTB records, while Table 2 classifies each Dys
patient based on a review of supplemental medical records according
to the newest Dys classification system.4 This most recent classification
system was not available for any of the subjects in this cohort at the
time of their clinical diagnosis. Table 2 also summarizes all available
data in terms of age at onset, body distribution, temporal pattern,
variability, associated features, occurrence of other neurological and
systemic manifestations, and etiologies (i.e., following the Axis I and II
of the newer classification).4 In terms of temporal patterns, 3 out of 13
Dys cases were classified as adulthood onset, 3 as early adulthood
onset, 6 as childhood onset, and 1 case of childhood-onset
Figure 1A. Quantification of SN Pigmented Neurons. The quadrants in the figure show how a randomly sampled pigmented neuron (first upper-right quadrant, 206
objective), and 6 randomly projected rays on that pigmented neuron intersect its cell body, nucleus, and nucleolus (respectively, upper-right, lower-left, and lower-right
quadrant). A 1006 oil immersion objective was used for all volumetric measurements and for each pigmented neuron. The green markers in each quadrant indicate the
point of measurement from which the areas of the cell body, nucleus, and nucleolus were calculated. The colored square upper-right quadrant represents the ‘‘counting
frame’’ used for the Optical Fractionator probe. The Stereo-investigator software automatically calculates the volumes of each single neuron computing various
parameters such as the thickness of the tissue, the disector height, and guard zones. Figure 1B. Tissue thickness, cell counting, volumetric measurability of nigral
pigmented neurons. SNc from a C brain (case#16), cut at different levels of thicknesses (40 mm and 10 mm), stained with CV, and inspected at two different magnifications
(106 and 206 objectives). The green circles in the inferior parts of the figure indicate the number of pigmented neurons measurable when pigmented neurons were
sampled using 40 mm-thick and 10 mm-thick tissue sections, respectively, with a 206 objective. Notably, the number of measurable pigmented neurons in SN cut at
10 mm of thickness (right of figure) is markedly higher due to the increased number of clear visible CV-stained nucleoli. The nucleolus was the established point of spatial
reference on this study. All measurements were performed using a 1006 oil-immersion, NA 1.30, neofluor ‘/0.17 objective. Abbreviations: C, Control; CV, Cresyl
Violet; SN, Substantia Nigra; SNc, Pars Compacta of Substantia Nigra.
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Sex Diagnosis (As Received) Genetics Other Relevant Medical
Data
1 (Dys)/1458 62 M Dystonia Neg for GAG del in
DYT1
None
2 (Dys)/1484 81 F Dystonia (started as
blepharospasm)
Not tested for DYT1
mutations
None
3 (Dys)/1850 50 F Dystonia (started at 42
years old: adulthood onset,
focal and segmental)
Not tested for DYT1
mutations
Mother with PD, multiple
drugs
4 (Dys)/4897 49 F Dystonia (generalized) Neg for GAG del in
DYT1
None
5 (Dys)/4880 44 F Dystonia (generalized
dystonia with involvement
of trunk, limbs, neck, and
flexion contractures in the
right leg; severe episodes








6 (Dys)/5145 84 F Dystonia (cervical dystonia
for .4 decades, head
begun to turn 43 years
before death with pain 20
years later, mouth
involvement 22 years later)




7 (Dys)/5414 95 F Dystonia (tremor since the





Not tested for DYT1
mutations
None
8 (Dys)/5421 81 F Dystonia Not tested for DYT1
mutations
None
9 (Dys)/1457 72 M Dystonia Neg for GAG del in
DYT1
None
10 (Dys)/1353 78 M Dystonia (severe bike-
automobile accident at 12
years old caused a
fractured skull, tremor and
posttraumatic dystonia
followed)
Neg for GAG del in
DYT1
None
Fewer Nigral Pigmented Neurons in Dystonia Iacono D, Geraci-Erck M, Peng H, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship






Sex Diagnosis (As Received) Genetics Other Relevant Medical
Data
11 (Dys)/4635 76 M Dystonia (generalized in
combination with cervical
myelopathy, initial cervical
dystonia at 27 years old)
Neg for GAG del in
DYT1
History of familial dystonia
symptoms (father and sister),
possDLB
















15 (C)/4921 73 F Control Not tested Gallbladder dysfunction, high
blood pressure
16 (C)/5357 51 F Control Not tested Drug overdose, suicidal
attempt
17 (C)/4788 48 F Control Not tested Multiple injuries resulting
from a motorcycle accident
18 (C)/4228 44 F Control Not tested None
19 (C)/5219 76 F Control Not tested None
20 (C)/M3642M 88 F Control Not tested Congestive heart disease
21 (C)/5274 64 F Control Not tested Hypertension, heart disease,
skin cancer
22 (C)/1818 76 M Control Not tested None
23 (C)/5171 79 M Control Not tested COPD
24 (C)/M3903M 71 M Control Not tested Coronary artery disease,
coronary angioplasty (twice),
COPD
25 (C)/1503 53 F Control Not tested Knee surgery after falling
26 (C)/1379 53 F Control Not tested High blood pressure, asthma
Abbreviations: C, Control; Cauc, Caucasian; COPD, Chronic Obstructive Pulmonary Disease; del, Deletion; Dys, Dystonia; DYT1, Dystonia Gene; F, Female; GAG,
Three-nucleotide Deletion; M, Male; Neg, Negative; PD, Parkinson’s Disease; possDLB, Possible Dementia with Lewy Bodies; UMBTB, University of Maryland Brain and
Tissue Bank.
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Table 2. Dys Patients Classified Following the Newer Classification System of Dystonia. The table shows the specific diagnosis of Dys for each patient in study
based on the Axis I (clinical features) and Axis II (etiologies) of the newer Dys classification system.4
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
1 (Dys) Dystonia Age at onset: not reported (probably
childhood-onset as for medical history)
Nervous system pathology: no evidence
of degeneration or structural lesions
Body distribution: not reported (probably
generalized as for medical history)
Inherited: possible
Temporal pattern: not reported Acquired: no
Variability: not reported Idiopathic: yes
Associated features: unknown/not
clinically significant
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
2 (Dys) Dystonia (started as
blepharospasm in 1983, 22 years
of dystonia history until death)
Age at onset: late adulthood Nervous system pathology: no evidence
of degeneration or structural lesions
Body distribution: initially focal, then
segmental (oromandibular dystonia with
jaw closure and lip pursing, facial
grimacing)
Inherited: no (aunt, mother’s sister, with
resting tremor)
Temporal pattern: static Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: headache (with
temporal and orbital pain)
Occurrence of other neurological/
systemic manifestations: tardive dyskinesia
secondary to adverse effects to
metoclopramide, moderate bradykinesia,
rigidity, and rest tremor; possible side
effects of various drugs used for the
treatment of the blepharospasm
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Table 2. Continued
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
3 (Dys) Dystonia (started at 42 years
old: adulthood onset, focal and
segmental)
Age at onset: late adulthood Nervous system pathology: evidence of
degeneration (SN)
Body distribution: focal, segmental (face,
neck, shoulders), dysphagia
Inherited: no (mother with PD)
Temporal pattern: static Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: unknown/not
clinically significant
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
4 (Dys) Dystonia (generalized) Age at onset: childhood Nervous system pathology: no evidence
of degeneration or structural lesion
Body distribution: generalized (with leg
involvement)
Inherited: no
Temporal pattern: progressive Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: headache (not
clinically significant)
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
5 (Dys) Dystonia (generalized) Age at onset: childhood Nervous system pathology: cerebellar
cortical degeneration
Body distribution: multifocal neck, trunk,
limbs), segmental (leg involvement)
Inherited: no
Temporal pattern: progressive Acquired: no
Variability: paroxysmal Idiopathic: yes
Associated features: pain, headache
Occurrence of other neurological/
systemic manifestations: frontal lobe
intracerebral hemorrhage (after many
years of generalized dystonia)
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Table 2. Continued
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
6 (Dys) Dystonia (cervical dystonia for
.4 decades)
Age at onset: early adulthood Nervous system pathology: no evidence
of degeneration or structural lesion
Body distribution: segmental (started as
cervical dystonia, then mouth and lingual
involvement)
Inherited: unknown (father with head
tremor)
Temporal pattern: progressive (mount
involvement, paraspinal muscles spasm,
spastic dysphonia)
Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: facial pain
Occurrence of other neurological/
systemic manifestations: resting hand
tremor (later, after many years cervical
dystonia appearance)
7 (Dys) Dystonia Age at onset: childhood Nervous system pathology: no evidence
of degeneration or structural lesion
Body distribution: segmental (truncal,
paraspinal spams with lordosis)
Inherited: no
Temporal pattern: diurnal Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: spastic dysphonia,
tremor started in 6th grade
Occurrence of other neurological/
systemic manifestations: unknown
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Table 2. Continued
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
8 (Dys) Dystonia Age at onset: late adulthood Nervous system pathology: evidence of
degeneration (SN), LB pathology
Body distribution: segmental (started as
blepharospasm then spasmodic dysphonia;
lip pursing, grimacing, and jaw opening)
Inherited: no
Temporal pattern: static Acquired: no
Variability: diurnal (getting worse with
action); not action-specific but with
associated
Idiopathic: yes
features of late-onset tardive dyskinesia
(oromandibular, pharyngeal, and facial
dystonia) due to possible side effects of
neuroleptic drugs (perphenazine/
amitriptyline)
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
9 (Dys) Dystonia Age at onset: childhood (probably) Nervous system pathology: cerebellar
atrophy (moderate)
Body distribution: generalized Inherited: no
Temporal pattern: progressive (probably) Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: unknown/not
clinically significant
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
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Table 2. Continued
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
10 (Dys) Dystonia (posttraumatic) Age at onset: childhood Nervous system pathology: cerebellar
atrophy, LBs in the SN and LC
Body distribution: focal (right hand) Inherited: no
Temporal pattern: static Acquired: yes, (posttraumatic)
Variability: persistent Idiopathic: no
Associated features: tremor (right hand)
Occurrence of other neurological/
systemic manifestations: unknown/not
clinically significant
11 (Dys) Dystonia (generalized in
combination with cervical
myelopathy; initial cervical
dystonia at 27 years old)
Age at onset: early adulthood Nervous system pathology: diffuse LB
pathology (brainstem, cortex), cerebellar
heterotaxia (white matter)
Body distribution: generalized Inherited: possible (reported familiarity
for movement disorders)
Temporal pattern: progressive (started
as cervical dystonia/torticollis then
progressed with arms and legs)
Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: marked diffuse
tremor
Occurrence of other neurological/
systemic manifestations: possible
dementia
12 (Dys) Dystonia Age at onset: early adulthood Nervous system pathology: no evidence
of degeneration or structural lesion
Body distribution: generalized Inherited: possible (daughter with
dystonia)
Temporal pattern: progressive Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: unknown/not
clinically significant
Occurrence of other neurological/
systemic manifestations: mastectomy
for breast cancer
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posttraumatic Dys. For body distribution, 6 out of 13 Dys cases were
classified as generalized, 6 as segmental/focal, and 1 segmental/focal
posttraumatic Dys.
All main neuropathologic data, postmortem delay (PMD, time
between death and autopsy) values, and causes of death are shown in
Table 3. The mean PMD was 11.7¡6.4 hours, with no significant
differences between the Dys (13¡6.7 hours) and C (10.4¡6.0 hours)
groups. The majority of Dys and C did not show signs of major recent
or remote ischemic, hemorrhagic lesions, metastatic infiltration, or
arteriovenous or congenital malformations. The exception was case#5
(Dys who showed microhemorrhages, probably due to the prolonged
periagonal status and history of remote hemorrhage from an
aneurysmatic rupture. Intima thickening was observed in most of the
arteries and arterioles in case #3, #12, #13, and #23, which was
compatible with arteriosclerotic disease (see Table 4).
Immunohistochemistry findings
Overall, 5/13 Dys and 5/13 C were positive for tau lesions. In the
majority of cases, tau lesions were sparse or rare (tau-NFT or tau-th),
and only two Dys cases (cases #7 and #8) had moderate levels of tau
lesions, mostly tau-th.
No C cases had a-synuclein-positive lesions (LBs or LNs), whereas
three Dys cases (#8, #10, and #11) did. These three cases were classified
as possible Lewy Body disease (possLBD) of the brainstem.40 None of
the SN samples were positive for 1–42 b-amyloid (diffuse amyloid or
neuritic plaques), ubiq, or pTDP43-positive cytoplasmic intraneuronal
inclusions. Ubiq-positive intranuclear inclusions (Marinesco bodies
[MB])44 were observed in some cases, and more often in Dys than C.
As a reminder, MB are eosinophilic intranuclear neuronal inclusions
observed in human brains that have an uncertain origin and pathologic
meaning. This intriguing finding has been reported previously;30
however, larger studies are necessary to confirm the higher frequency
of MB in Dys in general or in a specific Dys subtype. Table 4
summarizes the immunohistochemistry findings in both groups.
Quantitative findings: neuronal counting
A total number of 496,601¡130,010 and 648,926¡162,475
pigmented neurons were estimated in the SNs of the Dys and C
groups, respectively. The estimated nigral neuronal population in C
did not differ proportionally from previous stereologic studies that
assessed the entire SN length in control subjects.45,46
Histograms depicting the estimated nigral pigmented neuronal
counts and volumes are shown in Figure 2. The estimated nigral
pigmented neuronal population was calculated using neuronal
numbers weighted for each section thickness per each subject. A
significant reduction of pigmented neurons in SN of Dys versus C was
found (p50.01). A separate computation after exclusion of all positive
LB/LN and/or tau-NFT/th Dys (#6, #7, #8, #10, and #11) and C
(#15, #19, #20, #21, and #24) cases was also performed. This second
narrower computation confirmed a significant reduction of pigmented
neurons in the SN of Dys (n58) versus C (n57) (p50.01). No
significant differences in terms of neuronal counts were observed
between childhood-onset Dys and adulthood-onset Dys cases regard-
less of whether cases with co-occurring nigral pathologies were
Table 2. Continued
Subject# Diagnosis (As Received) Dystonia Diagnosis based on the Newer
Classification
Dystonia Diagnosis based on the Newer
Classification
Axis I Axis II
(Clinical Features) (Etiology)
13 (Dys) Dystonia Age at onset: childhood (probably) Nervous system pathology: no evidence
of degeneration or structural lesion
(metastatic cells in cerebrum, cerebellum,
brainstem)
Body distribution: generalized Inherited: no
Temporal pattern: progressive Acquired: no
Variability: diurnal Idiopathic: yes
Associated features: unknown/not
clinically significant
Occurrence of other neurological/
systemic manifestations: lung cancer
Abbreviations: C, Control; Dys, Dystonia; LB, Lewy Body; LC, Locus Coeruleus; PD, Parkinson’s Disease; SN, Substantia Nigra.
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Cause of Death Main Neuropathologic Findings
1 (Dys) 1,455 12 Natural No significant neuropathologic findings
2 (Dys) N/A 16 Natural Remote infarct in right parieto-occipital region; moderate cerebral
artery atherosclerosis
3 (Dys) N/A 3 Brain ischemic injury Acute hypoxic-ischemic encephalopathy, idiopathic SN degeneration
4 (Dys) N/A 16 Complications of the
disorder (multiple falls)
No significant neuropathologic findings
5 (Dys) N/A 20 Complications of the
disorder
Encephalomalacia involving frontal lobes with subarachnoid hematoma
due to ruptured berry aneurysm and surgical clip placement,
cerebellar cortical degeneration
6 (Dys) N/A 20 Complications of the
disorder
Generalized mild atrophy, arteriosclerotic cerebrovascular disease
7 (Dys) N/A 16 Complications of the
disorder
Neocortical gyral atrophy, arteriosclerosis with leukomalacia
8 (Dys) N/A 8 Complications of the
disorder
Diffuse brain atrophy, arteriosclerotic cerebrovascular disease, SN
degeneration with LBs in the SN and limbic cortex, AD-type lesions
(amyloid neuritic plaques and neurofibrillary tangles) in the
hippocampus
9 (Dys) N/A 12 Natural Microscopic remote infarct in the left caudate, moderate cerebellar
atrophy
10 (Dys) N/A 5 Septic shock, metabolic
acidosis, respiratory
failure
Mild cerebral hemispheric atrophy, rare LBs in the SN and LC, mild
cerebellar atrophy
11 (Dys) N/A 9 Complications of the
disorder
Amyloid neuritic plaques in the cortex; diffuse LBs in the SN, limbic
structures, and cortical regions; incidental cerebellar white matter
heterotopia
12 (Dys) N/A 26 Natural No significant neuropathologic findings
13 (Dys) N/A 6 Lung cancer Metastatic poorly differentiated carcinoma in the cerebrum,
cerebellum, and brainstem
14 (C) 1,309 6 Cardiac arrest Small cystic infarcts in the left parieto-occipital and frontal lobes
15 (C) N/A 13 Peritonitis No significant neuropathologic findings
16 (C) N/A 8 Atherosclerosis-
Cardiovascular disease
No significant neuropathologic findings
17 (C) N/A 17 Multiple traumatic injuries No significant neuropathologic findings
18 (C) 1,260 16 Coronary artery
atherosclerosis and
thrombosis
Acute hypoxic-ischemic encephalopathy in hippocampus
19 (C) N/A 3 Complications of cancer No significant neuropathologic findings
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excluded. Table 5 summarizes all comparisons for neuronal counting
between Dys and C with their numerical values and statistical
significance. See also Figure 4.
The mean for each type of volumetric measurement (cell body,
nucleus, and nucleolus) performed on nigral pigmented neurons of Dys
and C are shown in Table 5. A mean of 179.7¡56.3 nigral pigmented
neurons were volumetrically measured (range: 97–297) across all cases.
No difference was measured between the mean numbers of pigmented
neurons volumetrically measured in Dys (157.5¡40.0) and C
(201.9¡56.3). Importantly, no significant differences in mean cellular,
nuclear, or nucleolar volumes were found across all types of comparisons
between the Dys and C groups (Table 5). Table 6 shows the coefficient
error (CE) values for each performed measurement (counting and
volumes) for each subject in the study.
Discussion
To our knowledge, this is the first investigation to apply rigorous
neuropathologic quantitative methods to estimate the numbers and
volumes of nigral pigmented neurons in a consistent series of Dys and
an equivalent number of age-matched control brains that were
systematically assessed by specific immunohistochemistry protocols for
the individuation and exclusion of possible co-occurring pathologies
affecting the SN. Importantly, this is the largest quantitative analyses of
Dys brain tissue to date. Our results show that both adulthood- and
childhood-onset Dys patients exhibited significant reductions of
pigmented SN neurons compared to the C groups. Furthermore,
these quantitative analyses showed no significant differences between
Dys and C in terms of nigral pigmented neuronal volumes. These
findings would seem to exclude phenomena of atrophy or hypertrophy
for this type of pigmented neuron in non-DYT1 idiopathic Dys brains.
Previous studies describing semiquantitative or pathologic findings on
Dys brains mainly focused on genetic Dys, specifically DYT1
cases.20,29 Therefore, most of the findings from those studies do not
seem to be directly applicable to the Dys cohort examined here.
The previous report of larger pigmented neurons in the SN of
subjects with Dys (with and without GAG deletions)29 was not
confirmed in our non-DYT1 idiopathic Dys cohort. However, our
findings do not exclude the possibility that certain genetic forms of
Dys, such as DYT1 characterized by TorsinA protein dysfunction,
could induce specific cellular adaptation phenomena during brain
development. Indeed, it could be hypothesized that congenital
reductions or enlargements of specific neuronal types are present in
some specific sensory-motor cortical or subcortical areas47 as adaptive
or compensatory neuronal mechanisms against the subjacent initial
pathology. Phenomena of neuroplasticity48 in Dys patients illustrated
by some recent functional neuroimaging studies49 might support a
neurodevelopmental hypothesis of idiopathic Dys.
Limitations and strengths
Although the quantitative methods used in this study were very
similar to those used in unbiased stereology investigations, and we tried
to minimize confounding factors, it is important to consider our results






Cause of Death Main Neuropathologic Findings
20 (C) N/A 8 Congestive heart failure No significant neuropathologic findings
21 (C) N/A 20 Acute cerebrovascular
disease
No significant neuropathologic findings
22 (C) N/A 3 Acute cerebrovascular
disease
Mild to moderate atheromatosis of the circle of Willis,
arteriosclerosis of the middle- and small-sized intraparenchymal
arteries, microinfarct in the right Sommer’s sector (cornu ammonis 1
of the hippocampus)
23 (C) N/A 5 COPD, peripheral
vascular disease
No significant neuropathologic findings
24 (C) N/A 16 Cardiac arrest Brain edema
25 (C) N/A 5 Pulmonary
thromboembolism
No significant neuropathologic findings
26 (C) N/A 15 Respiratory distress No significant neuropathologic findings
Abbreviations: AD, Alzheimer’s Disease; BW, Brain Weight; C, Control; COPD, Chronic Obstructive Pulmonary Disease; Dys, Dystonia; LB, Lewy Body; LC, Locus
Coeruleus; N/A, Not Applicable; PMD, Postmortem Delay; SN, Substantia Nigra.
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Table 4. H&E and Immunohistochemistry Assessment of other SN Pathologies. The table shows the types and frequencies of co-occurring brain pathologies in the
SN of Dys and C subjects. Co-occurring brain pathologies were assessed by specific immunohistochemistry protocols for the following antigens: 1–42 b-amyloid,
hyperphosphorylated-tau, a-synuclein, ubiq, and phosphorylated-TDP43. The lesions considered were 1–42 b-amyloid diffuse and neuritic plaques,








1 (Dys) Neg Neg Neg Neg/Neg Neg Normal
2 (Dys) Neg Neg Neg Neg/Pos Neg Normal
3 (Dys) Neg Neg Neg Neg/Pos Neg Intimal thickening
4 (Dys) Neg Neg Neg Neg/Neg Neg Normal
5 (Dys) Neg Neg Neg Neg/Neg Neg Microhemorrhages
6 (Dys) Neg NFT and Th (sparse),
tau-glia
Neg Neg/Pos Neg Normal
7 (Dys) Neg NFT and Th (moderate) Neg Neg/Pos Neg Normal
8 (Dys) Neg Th (moderate) Pos (sparse) Neg/Neg Neg Normal
9 (Dys) Neg Neg Neg Neg/Neg Neg Normal
10 (Dys) Neg NFT (rare) Pos (rare) Neg/Pos Neg Normal
11 (Dys) Neg Th (sparse), pre-NFT (rare) Pos (rare) Neg/Neg Neg Normal
12 (Dys) Neg Neg Neg Neg/Neg Neg Intimal thickening
13 (Dys) Neg Neg Neg Neg/Pos Neg Intimal thickening
14 (C) Neg Neg Neg Neg/Neg Neg Normal
15 (C) Neg Th (sparse) Neg Neg/Neg Neg Normal
16 (C) Neg Neg Neg Neg/Neg Neg Normal
17 (C) Neg Neg Neg Neg/Neg Neg Normal
18 (C) Neg Neg Neg Neg/Neg Neg Normal
19 (C) Neg Th (rare) Neg Neg/Neg Neg Normal
20 (C) Neg NFT (rare) Neg Neg/Neg Neg Hyperemia
21 (C) Neg Th (rare) Neg Neg/Neg Neg Normal
22 (C) Neg Neg Neg Neg/Pos Neg Normal
23 (C) Neg Neg Neg Neg/Neg Neg Intimal thickening
24 (C) Neg Th (sparse) Neg Neg/Neg Neg Normal
25 (C) Neg Neg Neg Neg/Neg Neg Normal
26 (C) Neg Neg Neg Neg/Neg Neg Normal
Abbreviations: C, Control; Dys, Dystonia; H&E, Hematoxylin and Eosin; Neg, Negative; NFT, Neurofibrillary Tangle; Pos, Positive; SN, Substantia Nigra; TDP43, TAR
DNA-binding Protein 43; Th, Thread
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1) The obtained quantitative estimations were not based on the
entire length of the SN. Although we used well-established and
reliable stereology tools (such as the Optical Fractionator and
Nucleator probe) and precise histological, neuropathologic,
and clinical approaches (i.e., serial sectioning, anatomical
randomization, exclusion of co-occurring pathologies, same mean
age at death, etc.), this investigation cannot be defined as an
unbiased stereology study mainly due to the impossibility of
obtaining the entire structure of interest (SN). Our preliminary
novel findings need to be confirmed by unbiased stereological
investigations that include the entire anatomical extension of SN.
2) We assessed a low number of cases for each specific type of Dys. It
is highly probable that different types of Dys have different causes
and unique pathologic features. For example, it is highly probable
that adulthood- and childhood-onset forms of Dys represent two
different pathogenetic pathways. However, it cannot be totally
excluded that they share some common clinical and pathologic
features. Then, we cannot be certain that future larger
neuropathologic quantitative stereologic studies focusing on a
single type of Dys could confirm our findings only on some
specific type or group of Dys.
This investigation, however, also has several strengths:
1) To the best of our knowledge, this is the first clinicopathologic
correlative study performed on a relatively large number of
autopsy-Dys brains (n513) and an equivalent amount of autopsy-
confirmed age-matched control brains applying rigorous neuro-
pathologic quantitative methods to describe possible specific
characteristics (e.g., a reduced number of pigmented neurons in
the SN).
Figure 2. Histograms of the Estimated Mean Number of SN Pigmented Neurons in 13 Dys Patients and 13 C Subjects. The histograms on the left side
include all Dys and C brains, while those on the right show Dys and C data after exclusion of all brains with immunohistochemical evidence of co-occurring pathologies.
The lower part of the figure shows histograms of cell body, nuclear, and nucleolar mean volumes of pigmented neurons in the SN. The y-axis indicates mean volumetric
values expressed in mm3. *p,0.01. Abbreviations: C, Control; Dys, Dystonia; SN, Substantia Nigra.
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Table 5. Estimated Number of Pigmented Neuron Population and their Cellular and Subcellular Volumes in the SN of Dys and C Subjects. The table shows the
estimated number and cell body, nuclear, and nucleolar volumes of pigmented neurons (mean¡SD) in the SN of Dys and C across all considered subtypes. The
significance of p-values is indicated for each type of comparison. The significance was established when p,0.01.
Comparisons Estimated Number of
Pigmented Neurons (¡SD)
Cell Body Nuclear Nucleolar























































































































Abbreviations: C, Control; Dys, Dystonia; ns, not significant; SD, Standard Deviations; SN, Substantia Nigra.
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2) Extensive histopathologic analyses were performed on each single
Dys and C case, including possible co-occurring pathologies
affecting the SN. In our opinion, this type of immunohistochem-
istry assessment is essential to decrease the possibility that a lower
number of nigral pigmented neurons could be due to the
simultaneous presence of nigral degenerative pathologies. These
could indeed represent important confounders that are not
directly or necessarily related to the pathogenesis of idiopathic
forms of Dys. However, our findings do not exclude the possibility
that nigral or extranigral neurodegenerative phenomena (e.g.,
during aging), could contribute to the progression or initial
disease manifestations.
3) There was a remarkable effort in reclassifying most of the non-
DYT1 Dys autopsy cases available at UMBTB following the most
recent classification system changes.4 The reclassification was
based on the careful re-examination of all available medical
records. This effort was an important attempt to describe new
neuropathologic findings using precious brain tissues previously
donated and already available to the scientific community in
consideration of newer clinical views and modern neuropatholo-
gic quantitative and immunohistochemistry techniques.
Our neuropathologic morphometric-quantitative findings, which are
similar to the results of other recent pathologic studies,31,32 seem to
confirm the direct involvement of the SN in the pathomechanisms of
Dys. Importantly, the involvement of the SN in Dys with regard to a
reduced number of pigmented neurons (mainly dopaminergic cells) is
not necessarily or directly related to dopaminergic dysfunction per se
(i.e., dopaminergic function loss), or to a specific clinical phenomen-
ology of Dys. In fact, in a hypothetical and more global context of a
neurodevelopmental disorder, it is possible that other nondopaminer-
gic circuits and neurotrasmettitorial abnormalities (i.e., gamma-
aminobutyric acid, acetylcholine)50,51 could play important or even
major roles. Moreover, results from two clinical and functional
neuroimaging series52,53 support a more global view on Dys
phenomenology where the motor and nonmotor abnormalities
observed in Dys patients are associated with a broad spectrum of
abnormalities in multiple cerebral regions, some of which are
nondopaminergic. Furthermore, at a higher speculative level, a
neurodevelopmental hypothesis for idiopathic Dys (or some specific
form of it) that would not primarily involve dopaminergic dysfunction
(i.e., dopaminergic function loss) could help to explain the constant and
frustrating inefficacy of dopaminergic therapies in most Dys patients,
with the remarkable exception of DRD.
Larger studies are needed to confirm our novel findings on
idiopathic Dys. However, these preliminary results seem to suggest
the presence of a specific neuropathologic substrate in idiopathic Dys
in the form of a reduced number of nigral pigmented neurons that is
not due to a neurodegenerative process.
Some very important questions remain:
Figure 3. Co-occurring Pathologies in the SN of Dys Patients. Abbreviations: CD, Cervical Dystonia (subject Dys#6); Ch-on, Childhood-onset; Gen.,
Generalized (Subject Dys#13); LB, a-synuclein-positive Lewy Body; MB, Marinesco Body (intranuclear eosinophilic body); Tau-NFT, Tau-positive Neurofibrillary
Tangle; Tau-th, Tau-positive Thread; Ubiq+, Ubiquitin Positivity.
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Table 6. Estimated Number of Nigral Pigmented Neuronal Populations and Volumetric Measurements with Corresponding Values of Gunderson’s Coefficient
Errors in the Dys and C Groups. The table shows single values obtained in each Dys and C subject in terms of estimated number of pigmented nigral neurons
counted. Each mean neuronal counting estimation has a corresponding mean cell body, nuclear, and nucleolar volume for all examined subjects. CE is an










1 (Dys) 530,990.7 0.05 18,457.9 0.006 2,332.3 0.006 38.1 0.007
2 (Dys) 409,690.0 0.07 12,777.6 0.003 1,884.7 0.003 31.0 0.004
3 (Dys) 494,021.3 0.06 10,641.4 0.005 1,097.5 0.006 17.2 0.022
4 (Dys) 604,631.9 0.06 12,589.7 0.004 1,730.0 0.005 27.3 0.005
5 (Dys) 682,198.8 0.05 21,377.8 0.005 1,752.9 0.005 24.4 0.006
6 (Dys) 491,138.2 0.05 17,297.2 0.007 1,510.4 0.007 24.8 0.006
7 (Dys) 275,364.9 0.08 16,926.6 0.009 1,840.5 0.009 21.6 0.011
8 (Dys) 322,533.2 0.07 17,586.4 0.007 2,002.1 0.007 23.7 0.062
9 (Dys) 405,516.6 0.06 5,273.8 0.006 581.8 0.009 8.0 0.008
10 (Dys) 696,735.9 0.05 13,886.4 0.004 2,286.8 0.005 21.3 0.049
11 (Dys) 518,118.1 0.06 16,352.0 0.006 2,328.5 0.007 37.4 0.007
12 (Dys) 414,003.9 0.06 17,771.6 0.006 1,533.1 0.006 30.6 0.079
13 (Dys) 610,877.4 0.05 15,829.5 0.005 2,100.2 0.005 32.0 0.005
14 (C) 787,705.8 0.06 13,858.9 0.004 1,115.2 0.005 22.0 0.016
15 (C) 648,925.7 0.06 11,253.3 0.007 1,390.6 0.008 23.6 0.045
16 (C) 351,255.9 0.05 15,631.9 0.003 1,663.0 0.003 25.8 0.004
17 (C) 856,559.1 0.06 11,864.0 0.003 1,600.5 0.003 24.0 0.004
18 (C) 621,172.8 0.07 15,532.5 0.007 2,084.9 0.008 29.0 0.053
19 (C) 370,591.1 0.06 20,711.7 0.010 1,585.1 0.009 21.1 0.010
20 (C) 571,960.5 0.06 18,168.9 0.003 1,704.5 0.004 27.3 0.048
21 (C) 696,553.0 0.06 15,519.3 0.003 1,365.8 0.003 26.8 0.034
22 (C) 488,401.4 0.05 14,754.4 0.004 1,327.2 0.005 25.1 0.057
23 (C) 800,241.8 0.05 18,947.8 0.004 1,660.0 0.004 28.4 0.004
24 (C) 718,722.8 0.04 15,375.8 0.004 2,007.7 0.003 29.7 0.004
25 (C) 750,282.5 0.05 16,342.6 0.004 1,788.9 0.005 23.0 0.059
26 (C) 773,662.1 0.05 15,258.7 0.003 2,315.1 0.003 30.5 0.004
Abbreviations: C, Control; CE, Coefficient of Error (of Gunderson); Dys, Dystonia.
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1) In Dys brains, is the nigral pigmented neuronal reduction a loss
of neurons (neurodegenerative hypothesis), or does it represent,
as we hypothesize, a possible neurodevelopmental defect (neuro-
developmental hypothesis)?54 In support of the latter hypothesis is
the observation that volumetric measurements of nigral pigmen-
ted neurons in Dys cases were not significantly different from those
in C brains as would be expected if atrophic-neurodegenerative
processes were actually involved. These morphometric findings
are especially relevant considering that the reduction of nigral
pigmented neurons in Dys versus C remained significant even
after immunohistochemical exclusion of some copathologies
frequently associated with SN neuronal degeneration.
In addition, the absence of a difference in the number of nigral
pigmented neurons between the only available posttraumatic dystonia
case (#10) and C brains seems to support a neurodevelopmental
hypothesis for idiopathic Dys. In the future, larger studies of
posttraumatic and nonposttraumatic/idiopathic Dys could provide
pathologic findings that support or exclude a neurodevelopmental
defect of the SN in idiopathic Dys.
2) Does the nigral pigmented neuronal reduction primarily or
exclusively affect dopaminergic neurons? Does it specifically
impact the pars compacta or pars reticulata of the SN? It is
important to recall that the SN (and basal ganglia [BG] in
general) contains a considerable level of somatotopic neuronal
organization and neurotrasmettitorial complexity. It is not
possible to exclude then that fewer nigral pigmented neurons
could mainly affect specific subregions of the SN, thus influencing
specific cellular and pathogenetic mechanisms and causing
various clinical phenotypes and motor and nonmotor manifesta-
tions of Dys.
3) Does the nigral neuronal reduction (or loss) represent a cause or an
effect of other pathologic (or neurodevelopmental) phenomena?
Figure 4. Histograms of Estimated Mean Numbers of Pigmented Neurons. We quantified neurons in the substantia nigra (SN) of dystonia (Dys) vs. age-
matched control subjects (C) and compared counts in types of dystonia (adulthood-onset, childhood-onset, generalized, focal/segmental [foc/seg] dystonias). For each
measurement there are two histograms showing the obtained estimated number of neurons before and after exclusion of all nigral co-occurring pathologies (b-amyloid,
tau, Lewy bodies, and ubiquitin). All co-occurring nigral pathologies were assessed using immunohistochemistry protocols.
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Our preliminary quantitative findings, if confirmed, would offer novel
insight into specific neuronal alterations in idiopathic Dys. However,
these new findings need to take into account very complex
pathophysiologic mechanisms and possible pathologic differences
across the various forms of Dys.55–58 Nonetheless, partial overlapping
or common mechanisms among groups or subgroups of Dys with
similar clinical phenotypes remain possible.59
Future major efforts should include unbiased stereological analyses
in larger groups of different genetic and nongenetic forms of Dys to
confirm our observation of fewer pigmented neurons in the SN, and if
so, clarify whether this decrease is ‘‘congenital’’ or neurodegenerative
in nature. Another important issue is whether this cellular abnormality
is unique to the SN or specific forms of Dys.
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